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A massive scale-up of investments in malaria control 
resulted in an estimated 663 million lives saved in 
sub-Saharan Africa between 2000 and 2015,1 and 
11 countries have been certified malaria-free in the current 
millennium.2 Unfortunately, progress has stalled recently, 
and increases in malaria incidence were observed in several 
endemic countries.3 Continuing with business as usual is 
likely to jeopardise gains made in the past 20 years, and 
slow the progress towards elimination goals. Innovative 
and targeted measures are required to complement 
universal coverage with basic vector control and case 
management interventions, especially as heterogeneity in 
case incidence increases with declining transmission.
In the last mile to achieving elimination, malaria 
transmission and the appearance of asymptomatic and 
clinical infections become increasingly focal. Targeted 
reactive approaches, such as reactive case detection 
(RACD), are likely to form efficient interventions to 
eliminate infections and prevent onward transmission.4 
Supporting research on the effectiveness and operational 
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TACTs similar to those of the ACTs. Most importantly, in 
regions of southeast Asia with relevant ACT resistance 
(Cambodia, Thailand, and Vietnam), 42-day PCR-cor-
rected efficacies were 98% (95% CI 94–100) for dihydro-
artemisinin–piperaquine plus mefloquine versus a dismal 
48% (39–56) for dihydroartemisinin–piperaquine. The 
study was limited by a lack of blinding and by a relative 
lack of paediatric participants, who are the highest risk 
group for malaria worldwide, but who make up a small 
proportion of malaria cases in areas with ACT resistance.
These new results suggest that TACTs might replace 
ACTs. The addition of mefloquine to dihydroartemisinin–
piperaquine rescued the regimen from unacceptably 
poor efficacy, and mefloquine might additionally 
restrict selection of resistance to piperaquine. If safety 
and tolerability remain acceptable in follow-up studies, 
use of optimally dosed and formulated TACTs to treat 
P falciparum malaria might soon be appropriate in regions 
with artemisinin resistance. However, most cases of 
P falciparum malaria occur in regions without established 
artemisinin resistance. Should TACTs be implemented in 
these regions? On the one hand, TACTs might delay the 
development of resistance to multiple antimalarials, a 
vital benefit.10 On the other hand, despite promising initial 
results, adding another drug to established regimens will 
likely add to challenges regarding tolerability, toxicity, and 
drug interactions, especially considering known concerns 
for the partner drugs mefloquine and amodiaquine.11 On 
the ground, there might be little enthusiasm for changing 
highly efficacious regimens because implementing any 
policy change is difficult. Thus, this study offers promise 
for TACTs in regions with artemisinin resistance, but 
whether we should implement TACTs in other areas 
is uncertain. In any event, TACTs should be seen as a 
stopgap; novel combination therapies to treat malaria are 
greatly needed.
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feasibility of various forms of reactive focal strategies is 
required.5
In the low Plasmodium falciparum-endemic area of 
northeastern Namibia, Michelle Hsiang and colleagues6 
report in The Lancet an innovative approach to test 
two such interventions: reactive focal mass drug 
administration (rfMDA), implemented as presumptive 
treatment with artemether-lumefantrine, and reactive 
focal vector control (RAVC) by indoor residual spraying 
of the insecticide pirimiphos-methyl. The cluster-
randomised trial was done in 56 census enumeration 
area clusters. The study applied a two-by-two factorial 
design that allowed rfMDA to be compared with RACD 
(rapid diagnostic testing and treatment with artemether-
lumefantrine), RAVC to be compared with no RAVC, and 
rfMDA plus RAVC to be compared with RACD only. An 
intention-to-treat analysis was done, and the primary 
outcome was the cluster-level cumulative incidence of 
autochthonous malaria cases.
Testing an intervention in a low-transmission setting 
means that finding a sufficient number of cases to 
demonstrate effectiveness is difficult. Nevertheless, 
the study6 provided evidence that rfMDA and RAVC 
are both effective in reducing the incidence of malaria 
(rfMDA vs RACD, adjusted incidence rate ratio 0·52 
[95% CI 0·16–0·88], p=0·009; and RAVC vs no RAVC, 
0·48 [0·16–0·80], p=0·002), and that combining both 
interventions could be beneficial (rfMDA plus RAVC vs 
RACD only, 0·26 [0·10–0·68], p=0·006).
Simultaneously, this study6 also highlights the dif-
ficulty inherent in demonstrating the effectiveness 
of interventions in a real-world setting.7 The study 
period,6 which was originally planned for 2 years, had to 
be limited to 1 year because of unforeseen operational 
challenges resulting from an increase in malaria cases 
in the first year. The observed outcomes are thus short-
term results, and the sustainability of the achieved 
coverage and resulting effects are yet to be determined. 
Longer-term evaluations are essential, as effectiveness 
might reduce over time because of epidemiological 
fluctuations and health system constraints;7,8 and 
studies9 in other settings have found the effect of 
targeting hotspots to be transient. This requires long-
term commitment from funding agencies, stamina 
from researchers and implementers, and acceptance 
from the scientific community that generating 
comprehensive results requires time.
An imbalance in the baseline characteristics across 
the study arms6 could be adjusted for, thanks to 
a robust study design that measured the relevant 
indicators. However, the absence of buffer zones 
between implementation clusters could have led to 
a contamination effect that reduced the observed 
effectiveness of RAVC in this study. Furthermore, RAVC 
by indoor residual spraying of an insecticide has a residual 
effect that lasts for months (unlike RACD and rfMDA) 
and might therefore prevent onward transmission from 
future importations. The effectiveness of RAVC requires 
further investigation in longer running trials, as it could 
become a cornerstone of malaria elimination strategies.
The study6 in Namibia was implemented as a trial, 
and hence with substantial external support. A high 
coverage (>80%) was achieved for all interventions. 
Case management, though not discussed in detail in 
the manuscript, could well have been better (in terms of 
coverage and quality) than in a non-study context. Most 
importantly, the study team invested substantial time 
and effort in working with local authorities to improve the 
completeness and timeliness of the passive surveillance 
system. As modelling suggests that the effectiveness of 
RACD (and probably also rfMDA) depends strongly on 
the quality of the passive surveillance system,10 these 
interventions might not work equally as well outside 
of a trial setting. Additionally, the frequency of malaria 
importation from higher endemic areas, mosquito 
ecology and behaviour, and the presence of other malaria 
species (most notably Plasmodium vivax) could influence 
the effectiveness of the interventions tested in Namibia.
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Older patients who present with a non-ST-segment 
elevation acute coronary syndrome (NSTE-ACS) are at 
particular risk of recurrent ischaemic events, but also 
of bleeding complications.1 Choosing the optimal dual 
antiplatelet strategy for the ageing patient with ACS can 
thus present a dilemma in daily practice. Should dual 
antiplatelet therapy in an older patient include the less 
potent P2Y12 inhibitor clopidogrel, thus minimising 
bleeding risk, or should a more potent P2Y12 inhibitor 
such as ticagrelor or prasugrel be used to avoid recurrent 
ischaemic events? In addition, the ideal dual antiplatelet 
therapy duration for these patients remains unclear. 
Unfortunately, guidelines do not contain specific 
age-tailored advice, reflecting the conflicting and 
suboptimal evidence from primary clinical studies.1–5
Additional guidance for treating older NSTE-ACS 
patients now comes from the POPular AGE trial by 
Marieke Gimbel and colleagues,6 reported in The Lancet. 
In this study, 1002 patients with NSTE-ACS, aged 70 years 
or older (64% male and 36% female), were randomly 
assigned to either clopidogrel or one of the two more 
potent P2Y12 inhibitors, ticagrelor or prasugrel, for 
1 year after their acute event. 475 (95%) patients received 
ticagrelor in the ticagrelor or prasugrel group; therefore, 
the results show a comparison between clopidogrel and 
ticagrelor. The primary outcome, any bleeding requiring 
medical intervention, was significantly lower in the 
clopidogrel group (88 [18%] of 500 patients) than in 
the ticagrelor group (118 [24%] of 502; hazard ratio 
[HR] 0·71, 95% CI 0·54–0·94; p=0·02). The reduction in 
bleeding risk with clopidogrel was not only driven by 
fewer minor bleedings, but also by a lower risk of major 
bleeding. There were also five fatal bleedings in the 
ticagrelor group versus none in the clopidogrel group. Net 
clinical benefit, a coprimary endpoint, including bleeding 
and ischaemic outcomes, was similar for both treatment 
groups (p=0·03 for non-inferiority). Although five stent 
thromboses occurred with clopidogrel versus none 
with ticagrelor, there were no differences in myocardial 
infarction or cardiovascular death. Overall, the study 
showed that in NSTE-ACS patients, aged 70 years or 
older, clopidogrel can decrease bleeding risk in a clinically 
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The limitations and challenges in the study by Hsiang 
and colleagues6 do not diminish the relevance of their 
findings. Challenges with RACD due to high levels of 
subpatent infections not detected by conventional 
diagnostic tools have been found elsewhere.11 Bold but 
evidence-supported actions are required to accelerate 
progress towards malaria elimination wherever pos-
sible. The presented evidence on rfMDA and RAVC, 
alone or in combination, should encourage larger scale 
implementation of these strategies in other settings, 
accompanied by well designed, long-term evaluations.
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